David Egilman, M.D. Publications

PUBLICATIONS

  1. Egilman, D., Reinert, A.: The Origin and Development of the Asbestos Threshold Limit Value: Scientific indifference and corporate influence. Int. J. Health Serv. 25:667–696, 1995.
  2. Durand, K. and Egilman, D., Possible Corruption Of IH Literature By DuPont: The Imron Respirator Studies, Am Ind. Hyg.. Assoc. J. 56:817–825, August 1995.
  3. Egilman, D., Reinert, A.: Asbestos Exposure and Lung Cancer: Asbestosis is Not Necessary. Am. J. Ind. Med. 30:398–406, 1996.
  4. Schnoor, T., Steenland, K, Eglend, G, Boeniger, M, Egilman, D, Mortality of Workers Exposed to Toluene Diisocyante in the Polyurethane Foam Industry, Occ. Env. Med., 53:703–707, 1996.
  5. Egilman, D., Wallace, W., Stubbs, C., and Mora-Corrasco, F. “A Little Too Much of the Buchenwald Touch? Military Radiation Research at the University of Cincinnati, 1960–1972.” Accountability in Research Vol. 6, pp. 63–102, 1998.
  6. Egilman, D., Wallace, W., Stubbs, C., and Mora-Corrasco, F. “Ethical Aerobics: ACHRE’s Flight from Responsibility.” Accountability in Research Vol. 6, pp. 15–61, 1998.
  7. Egilman, D., Wallace, W., Hom, C., W. R. Grace Corporate Corruption of the Medical Literature, Accountability in Research Vol. 6, pp.127–147, 1998.
  8. Egilman, D.S., Kim, J., Biklen, M. Proving Causation: The Use and Abuse of Medical and Scientific Evidence Inside the Courtroom — An Epidemiologist’s Critique of the Judicial Interpretation of the Daubert Ruling. Food and Drug Law Journal 58:2, 2003.
  9. Egilman, D.S., Fehnel, C., Bohme, S.R. Exposing the “Myth” of ABC: A Critique of the Canadian Asbestos Mining Industry-McGill Chrysotile Studies. Amer J Ind Med 44:5, 2003.
  10. Egilman D.S., Bagley S., Biklen M., Golub A.S., Bohme S.R. The Beryllium “Double Standard” Standard. International Journal of Health Services 33:4, 2003, pages 769–812.
  11. Egilman D.S., Bohme S.R. “A Brief History of Warnings.” Handbook of Warnings, ed. Michael Wogalter. Mahwah, NJ: Lawrence Erlbaum Associates, 2006.
  12. Bohme S.R., Egilman D.S., “Consider the Source: Warnings and Anti-Warnings in the Tobacco, Automobile, Beryllium and Pharmaceutical Industries.” Handbook of Warnings, ed. Michael Wogalter. Mahwah, NJ: Lawrence Erlbaum Associates, 2006.
  13. Egilman, D. Suppression Bias at the Journal of Occupational and Environmental Medicine. Int J Occup Environ Health 2005: 11: 202–204.
  14. Egilman D.S., Bohme S.R, Guest Editors, Special Issue: The Corporate Corruption of Science. Int J Occup Environ Health 2005: 11(4).
  15. Egilman D.S., Bohme S.R. Over a Barrel: Corporate Corruption of Science and Its Effects on Workers and the Environment. Int J Occup Environ Health 2005: 11(4), 331–337.
  16. Egilman D.S., Billings M.A. Abuse of Epidemiology: The Automobile Manufacturers Manufacture a Defense to Asbestos Liability. Int J Occup Environ Health 2005: 11(4), 360–371.
  17. Bohme S.R., Zorabedian J, Egilman D.S. Maximizing Profit and Endangering Health: Corporate Strategies to Avoid Litigation and Regulation Int J Occup Environ Health 2005: 11(4), 338–348.
  18. Egilman D.S, Scout. Corporate Corruption of Science: The Case of Chromium (VI). Int J Occup Environ Health 2005: 12(2), 184–191.
  19. Egilman D. S., Presler A. H. Report of Specific Cardiovascular Outcomes of the ADVANTAGE Trial Ann Intern Med 2006 144:. 781–781
  20. Bailar JC et al. FIOH-sponsored newsletter misrepresents asbestos hazards in Zimbabwe, Int J Occup Environ Health. 2006 Jul–Sep;12(3):254–8.
  21. Egilman D.S., Mailloux C.J., Valentin, C.S. Popcorn Worker Lung Caused by Corporate and Regulatory Negligence: An Avoidable Tragedy. Int J Occup Environ Health 2007. 13(1): 85–22. Egilman D.S., Howe S. Against Anti-health Epidemiology: Corporate Obstruction of Public Health via Manipulation of Epidemiology. Int J Occup Environ Health 2007. 13(1):118–124.
  22. Krumholz HM, Ross JS, Presler AH, Egilman DS. What have we learnt from Vioxx? BMJ 2007 Jan 20; 334(7585):120–3.
  23. Egilman D.S., Scout, Kol , L., Hegg, L., Bohme, S. R. Commentary: Manipulated Data In Shell’s Benzene Historical Exposure Study. Int J Occup Environ Health 2007: 13(2), 222–232
  24. LaDou J, Teitelbaum DT, Egilman DS, Frank AL, Kramer SN, Huff J. American College of Occupational and Environmental Medicine (ACOEM): a professional association in service to industry. Int J Occup Environ Health. 2007 Oct–Dec;13(4):404–26.
  25. Egilman D.S., Presler A.H., Hegg L.A., Billings M.A., Scout, Valentin C.S. Merck-y Ethics and Sacrificing Health for Profit: ADVANTAGE Vioxx Trial Demonstrates a Profile of Deceit. International Journal of Health Services. In press.
  26. De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N., Strengthening primary care: addressing the disparity between vertical and horizontal investment.Br J Gen Pract. 2008 Jan;58(546):3–4
  27. De Maeseneer J, van Weel C, Egilman D, Mfenyana K, Kaufman A, Sewankambo N, Flinkenflögel M., Funding for primary health care in developing countries, BMJ. 2008 Mar 8;336(7643):518–9.
  28. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008 Apr 16;299(15):1800–12.
  29. Kevin P. Hill, Joseph S. Ross, David S. Egilman, and Harlan M. Krumholz The ADVANTAGE Seeding Trial: A Review of Internal Documents Ann Intern Med, Aug 2008; 149: 251–258.
  30. Egilman DS, Bohme SR. IJOEH and the critique of bias. Int J Occup Environ Health. 2008 Apr–Jun;14(2):147–51.
  31. Egilman D. Ford, General Motors, Chrysler, asbestos and a “Sane appreciation of the risks,”Int J Occup Environ Health. 2009 Jan–Mar;15 (1):109–10.
  32. Egilman D. Fiber types, asbestos potency, and environmental causation: a peer review of published work and legal and regulatory scientific testimony. Int J Occup Environ Health. 2009 Apr–Jun;15(2):202–28.
  33. Swanson C, Mosley H, Sanders, D, Egilman D, De Maeseneer J, Chowdhury M, Lanata C, Dearden K, Malcolm B, Call for global health-systems impact assessments, The Lancet, July 2, 2009.
  34. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM, Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance, Arch Intern Med. 2009 Nov 23;169(21):1976–85.
  35. Egilman D, Menéndez LM. A case of occupational peritoneal mesothelioma from exposure to tremolite-free chrysotile in Quebec, Canada: A black swan case. Am J Ind Med. 2010 Aug 18. PubMed PMID: 20721899.
  36. Ross, JS, Madigan D ,Konstam MA, Egilman DS, Krumholz HM, Persistence of Cardiovascular Risk After Rofecoxib Discontinuation, Arch Intern Med, Dec 13/27, 2010; 170: 2035–2036.

OTHER PUBLICATIONS

  1. Egilman, D., Alcoholism and Liver Injury (letter), NEJM., 208:260, 1978.
  2. Ahrenholz, S., Egilman, D., Health Hazard Evaluation — Wooster, Ohio: Report No. 82-223-1340. Cincinnati, Ohio: National Institute for Occupational Safety and Health, 1982.
  3. Stephenson, RL., Egilman, D., Health Hazard Evaluation — Rockport, Indiana: Report No. 82-359-1382. Cincinnati, Ohio: National Institute for Occupational Safety and Health, 1983.
  4. Salisbury, S., Egilman, D., Health Hazard Evaluation — Port Gibson, Mississippi: Report No. 83-132-1508. Cincinnati, Ohio: National Institute for Occupational Safety and Health, 1984.
  5. Egilman, D., Lichty, P., Cost and Benefits of Hepatitis Prophylaxis (letter), JAMA, 251:2794, 1984.
  6. Kelly, R.M., Egilman, D.S., Gordon, JE. Long Term Effects Following Isocyanate Exposure (letter), J. Occup. Med., 27(7):469–470, 1985.
  7. Frumkin, H., Egilman, DS. Christiani, D., Pepper, L., Sprince, N., Himmelstein, J. Asbestos Related Disease (letter), JAMA, 254(10):1307–1308, 1985.
  8. Egilman, D., Greer D. S. International exchange for medical training (letter), NEJM., 314:652, March 6, 1986.
  9. Egilman, D., Greer, D.: International Health Needs (commentary), International J. Of Dermatology, 26(6):351–353, 1987.
  10. Schnorr, T., Egilman, D.: Health Effects of Toluene Diisocyanate, In: Zenz, Carl, Occupational Medicine, Principles and Practical Applications, 2nd ed., Year Book Medical Publishers, Chicago 1988.
  11. Egilman, D., Ethics of Mandatory Masturbation (letter), JOM, 30; 12:992, December 1988.
  12. Egilman D., Missing Information-The Enemy of Chemical Safety, Industry November 1989.
  13. Egilman D., The Training Exchange: An opportunity to serve (letter), Am J Public Health (1989 Nov) 79(11):1570.
  14. Egilman, D., Haag, Beverly J.: Guideline for Medical Surveillance, Industry, April 1989.
  15. Egilman, D., The Training Exchange: An Opportunity to Serve, AJPH, Volume 79, No. 11, Page 1570, 1989.
  16. Egilman, D., The emperor has no clothes: TLV’s and Corporate influence, Am Ind. Hyg. Assoc. J., 187–188, March 1990.
  17. Crossgrove, W., Egilman, D., Heywood, P. et al.: Colonialism, International Trade, and the Nation-state, In: Newman, L., Crossgrove, W., Kates, R., et al., Hunger in History: Food Shortage, Poverty and Deprivation. Cambridge, MA: Basil Blackwell Inc., 1990.
  18. Hardy, HL., Egilman, D.: Corruption of Occupational Medical Literature: The Asbestos Example (letter). Am. J. Ind. Med. 20(1):127–129.1991.
  19. Egilman, D., Public Health and Epistemology. Am. J. Ind. Med, 22:457–459, 1992.
  20. Egilman, D., The Past Foretells the Future. Links 10(1):13–15.1993.
  21. Egilman, D., Hardy, HL: Manipulation of Early Animal Research on Asbestos Cancer (letter). Am. J. Ind. Med. 24:787–791.1993.
  22. Ziem, G., Cone, J., Castleman, B., Cunningham, K., Egilman, D.: Health-Based Exposure Limits. Draft 7, October 23, 1993, HEEL Committee.
  23. Egilman, D., Reinert, A.: What Is Informed Consent? Washington Post, January 14, 1994: P 24.
  24. Ziem, G., Cone, J., Castleman, B., Cunningham, K., Egilman, D.: Chemical Exposure Guidelines, Version 9. San Jose, CA: APHA Committee on Occupational Safety and Health. October 1995.
  25. Egilman, D., Reinert, A.: Commentary: The Asbestos TLV: Early Evidence of Inadequacy. Am. J. Ind. Med., 30:369–370, 1996. Egilman D, Punnett L, Hjelm EW, Welch L. Evidence for wor-krelated musculoskeletal disorders. J Occup Environ Med. 1996 Nov;38(11):1079–80; author reply 1083–4.
  26. Goldin, G., Goldin, A., Egilman, D.: Mesothelioma an Unwarranted Causal Model (letter) JOM, 38:3,239–240, 1996.
  27. Egilman, D., Punnett L, Wigaeus Hjelm E., Welch L., Keyboarding can cause Injury (letter), JOEM, 38:10 1079–1081, November 1996.
  28. Egilman, D., Stubbs, C., “Evaluating the Health Risks of Silicone Breast Implants,” Letter to the editor, NEJM Vol 335, Number 315, October 10, 1996.
  29. Egilman, D., Wallace, W., Stubbs, C., and Mora-Corrasco, F. “A Little Too Much of the Buchenwald Touch? Military Radiation Research at the University of Cincinnati, 1960–1972.” Accountability in Research Vol. 6, pp. 63–102, 1998.
  30. Egilman, D., Wallace, W., Stubbs, C., and Mora-Corrasco, F. “Ethical Aerobics: ACHRE’s Flight from Responsibility.” Accountability in Research Vol. 6, pp. 15–61, 1998.
  31. Egilman, D., Wallace, W., Hom, C., W. R. Grace Corporate Corruption of the Medical Literature, Accountability in Research Vol. 6, pp.127–147, 1998.
  32. Egilman, D., Hom, C., Commentary: Corruption of the Medical Literature: A Second Visit, Am. J. Ind. Med., 34:4 401–404, October 1998.
  33. Egilman, D., Walta, M., Letter to the Editor: Breast Implant Verdicts Resulted From Corporate Misconduct and Legitimate Science, Am. J. Pub. H., 89:11 1763–1764, November 1999.
  34. Egilman, D., Hornblum, A., Letter to the Editor: Guinea Pigs Behind Bars, The Boston Globe, Monday, November 29, 1999.
  35. Egilman, D., Reinert, A., Letter to the Editor: Corruption of Previously Published Asbestos Medical Literature: The 1958 QAMA Miner Cancer Study, Archives Env. Health, Vol 55, No. 1, Jan/Feb 2000.
  36. Egilman, D., Letter to the Editor: Researchers Should Talk To Workers, Am. J. Ind. Med., 37:6 668, June 2000.
  37. Egilman, D., Letter to the Editor: Re: Researchers Should Talk to Workers, Am. J. Ind. Med., 39:3 347, March 2001.
  38. Ludwig E.R., Madeksho, L., and Egilman, D., Letter to the Editor, Commentary, Re: Mesothelioma and Lung Tumors Attributable to Asbestos Among Petroleum Workers, Am. J. Ind. Med., 3.
  39. Egilman, D., Asbestos Screenings, Am. J. Ind. Med., 42:2, August 2002.
  40. Egilman, D., Bagley, S., Connolly, S., Letter to the Editor: Anything But Beryllium: The Beryllium Industry’s Corruption of Safety Information, Am. J. Ind. Med., 42:3, September 2002.
  41. Egilman, D., Ehrle, L.H. Letter: Handling Conflicts of Interest between Industry and Academia. JAMA. 2003; 289;3240.
  42. Egilman, D., Ehrle, L.H. Letter: Handling Conflicts of Interest between Industry and Academia. JAMA. 2003; 289;3240. Axelson O, Balbus JM, Cohen G, Davis D, Donnay A, Doolittle R, Duran BM, Egilman D, Epstein SS, Goldman L, Grandjean P, Hansen ES, Heltne P, Huff J, Infante P, Jacobson MF, Joshi TK, LaDou J, Landrigan PJ, Lee PR, Lockwood AH, MacGregor G, Melnick R, Messing K, Needleman H, Ozonoff D, Ravanesi B, Richter ED, Sass J, Schubert D, Suzuki D, Teitelbaum D, Temple NJ, Terracini B, Thompson A, Tickner J, Tomatis L, Upton AC, Whyatt RM, Wigmore D, Wilson T, Wing SB, Sharpe VA. Re: Regulatory Toxicolgy and Pharmacology. Int J Occup Environ Health. 2003 Oct–Dec;9(4):386–9; author reply 389–90
  43. Jacobson MF, Sharpe VA, Angell M, Ashford NA, Blum A, Chary LK, Cho M, Coull BC, Davis D, Doolittle RF, Egilman D, Epstein SS, Greenberg M, Hooper K, Huff J, Joshi TK, Krimsky S, LaDou J, Levenstein C, Miles S, Needleman H, Pellegrino ED, Ravanesi B, Sass J, Schecter A, Schneiderman JS, Schubert D, Soffritti M, Suzuki D, Takaro TK, Temple NJ, Terracini B, Thompson A, Wallinga D, Wing S. Editorial policies on financial disclosure. Nat Neurosci. 2003 Oct;6(10):1001.
  44. Egilman, D., Bohme, S.R. Threshold Limit Values: Should We Trust Them? NECOEM Reporter 2:7, Spring 2003.
  45. Angell, M et al. Letter to the Editor [Journal Should Strengthen Conflict of Interest Disclosure Policy] Nature Neuroscience 6: 10, October 2003.
  46. Egilman D., Bohme S.R. Commentary: Attorney-directed screenings can be hazardous. Amer J Ind Med. 45:3, 2004, pages 305–307.
  47. Egilman D., Roberts M.L. Letter to the Editor. RE: The Controlled Use of Asbestos. Int J Occup Environ Health. 10:1, 2004, pages 99–103.
  48. Breihl, Jaime et al. Letter: Texaco and Its Consultants. Int J Occ Env Health 11: 217–220, 2005.
  49. Egilman D.S., Bohme S.R. Letter: Chevron-Texaco’s Science. Int J Occ Env Health 11(4): 456–457.
  50. Egilman D.S. Bohme S.R. Vioxx Marketing: Merck’s Failure to Warn. International Ergonomics Association 2006 Conference Proceedings.
  51. Bohme S. R., Egilman D.S. Pharmaceutical Warnings and “Direct to Consumer” Marketing. International Ergonomics Association 2006 Conference Proceedings.
  52. Egilman D.S., Bohme SR. In Reply. Int J Occup Environ Health 2005: 12(2), 182–186.
  53. Egilman D.S., Howe, S. In Reply. Int J Occup Environ Health 2007: 13(1), 134–136.
  54. Egilman D.S., Presler, A. H., Valentin, C. S. Avoiding the Regulatory Capture of the FDA. Archives of Internal Medicine. 167:2007, page 732.
  55. Egilman D, Tweedale G, McCulloch J, Kovarik W, Castleman B, Longo W, Levin S, Bohme SR P.W.J. Bartrip’s attack on Irving J, Selikoff.Am J Ind Med. 2004 Aug;46(2):151–5.
  56. Bohme SR, Egilman D. Beyond reputation: debate on the role of corporate influence in occupational and environmental medicine. New Solut. 2008;18(3):317–24.
  57. Abdo KM, Camargo CA Jr, Davis D, Egilman D, Epstein SS, Froines J, Hattis D, Hooper K, Huff J, Infante PF, Jacobson MF, Teitelbaum DT, Tickner JA. Letter to U.S. FDA commissioner. Questions about the safety of the artificial sweetener aspartame
  58. Egilman, D., Seeding Trials: Just Say no, BMJ 2009; 339 11/2/ 2009.
  59. Swanson RC, Mosley H, Sanders D, Egilman D, et al., Call for global health-systems impact assessments, Lancet. 2009 Aug 8;374(9688):433–5.
  60. Takaro T, Davis D, Van Rensburg J, et al., Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world. Int J Occup Environ Health. 2010 Apr–Jun;16(2):241–8.
  61. Egilman D., Continued Controversy on Chrysotile Biopersistence, Response, Int J Occup Environ Health. 2011 Jam–Mar;17(1):99–102.